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ABSTRACT
Cervical cancer is the third most common cancer in women worldwide, leading 
to about 300,000 deaths each year. Most cervical cancers are caused by human 
papillomavirus (HPV) infection. However, persistent transcriptional activity of HPV 
oncogenes, which indicates active roles of HPV in cervical cancer maintenance and 
progression, has not been well characterized. Using our recently developed assays for 
comprehensive profiling of HPV E6/E7 transcripts, we have detected transcriptional 
activities of 10 high-risk HPV strains from 87 of the 101 cervical tumors included in 
the analysis. These HPV-positive patients had significantly better survival outcome 
compared with HPV-negative patients, indicating HPV transcriptional activity as a 
favorable prognostic marker for cervical cancer. Furthermore, we have determined 
microRNA (miRNA) expression changes that were correlated with tumor HPV status. 
Our profiling and functional analyses identified miR-9 as the most activated miRNA 
by HPV E6 in a p53-independent manner. Further target validation and functional 
studies showed that HPV-induced miR-9 activation led to significantly increased cell 
motility by downregulating multiple gene targets involved in cell migration. Thus, 
our work helps to understand the molecular mechanisms as well as identify potential 
therapeutic targets for cervical cancer and other HPV-induced cancers.
INTRODUCTION
Human papillomavirus (HPV) infection can lead to 
a variety of human cancers [1, 2]. It has been shown that 
most cervical cancers are caused by HPV infection [3, 
4]. Two oncogenes encoded in the HPV genome, E6 and 
E7 play critical roles in cervical cancer development [5]. 
Expression of HPV E6 leads to degradation of p53, which 
is a critical tumor suppressor regulating cell growth and 
apoptosis. Furthermore, HPV E7 binds and deactivates 
another important tumor suppressor, retinoblastoma 
protein (Rb). In most cases, expression of both E6 and E7 
are required for oncogenic transformation.
In addition to deactivating tumor suppressors p53 
and Rb, HPV infection leads to many cellular changes 
during cervical cancer development [6]. However, the 
impact of HPV infection on host microRNA expression 
has not been well characterized. MicroRNAs (miRNAs) 
are small non-coding RNA molecules (~23 nucleotides) 
that downregulate the expression of their gene targets [7]. 
Both computational and experimental studies indicate 
that thousands of human protein-coding genes are directly 
regulated by miRNAs. Thus, miRNAs play important 
regulatory roles in many physiological processes as well 
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as a variety of disease states such as cancer [8]. Relevant 
to this study, altered miRNA expression profiles have 
been reported in cervical carcinomas as compared with 
normal cervix [9-15]. In addition, miRNA expression 
changes have been used as biomarkers for cervical cancer 
prognosis [16]. However, it is not clear whether these 
cervical cancer-related miRNA changes were directly 
caused by HPV infection, or simply indirect effects from 
cervical cancer progression in general. To specifically 
characterize miRNA expression changes that are related 
to HPV activity, we determined the expression status of 
HPV E6 and E7 transcripts in 101 cervical carcinomas. 
Transcriptional activity of HPV was then correlated to 
miRNA expression profiles to identify HPV-associated 
miRNA changes. In this way, we have identified miR-
9 as the most activated miRNA by HPV E6 in cervical 
cancer, and showed that both the transcriptional activity 
of HPV E6/E7 and miR-9 were prognostic markers for 
cervical cancer. Further target validation and functional 
cell biology analyses showed that HPV-induced miR-9 
activation led to significantly increased cell motility by 
downregulating multiple gene targets that are involved in 
cell migration, which may contribute to the progression of 
cervical cancer.
RESULTS
HPV transcriptional activity was a prognostic 
marker for cervical cancer
One hundred and one cervical carcinomas were 
profiled for HPV expression (patient characteristics listed 
in Table 1). To detect and quantify HPV transcriptional 
activities, we have recently developed real-time PCR-
based assays for expression profiling of E6 and E7 
transcripts from 13 high-risk HPV types [17]. By 
performing these assays, HPV transcriptional activity was 
detected in 87 of the 101 cervical cancer cases (86.1%). 
Among all the HPV-positive cases, ten distinct HPV types 
were detected (Figure 1A). Consistent with previous 
studies, HPV16 and HPV18 were the most common 
types. In addition, eight other HPV strains were also 
detected, including types 31, 33, 35, 45, 52, 58, 59 and 66. 
For each of the 87 HPV-positive cases, both E6 and E7 
Figure 1: HPV expression profile in 101 cervical tumors. (A) The HPV status of the cervical tumors was determined by expression 
profiling of the E6 and E7 transcripts from 13 high-risk HPV types. The majority of these tumors (n=59) were HPV type 16 positive. 
Collectively, ten HPV types were detected in 87 of the 101 tumors. (B) Prognostic significance of tumor HPV status. The 101 cancer cases 
were stratified by HPV status and correlated to disease outcomes, as evaluated by five-year overall survival or recurrence-free survival. 
Tumor HPV status was significantly associated with better patient survival.
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transcripts were detected. For most tumors, both E6 and 
E7 transcripts from the same HPV strain were detected. 
However, double HPV infections were detected in two 
cases, as both E6 and E7 transcripts were detected from 
each of the two HPV strains, HPV16/58 and HPV16/35, 
respectively.
Tumor HPV expression status was correlated to 
patient outcome with Cox regression analysis. As shown 
in Figure 1B, patients with HPV-positive tumors had 
significantly better survival outcome than those with HPV-
negative tumors, as evaluated by both five-year overall 
survival and recurrence-free survival (P = 0.026 and 0.033 
with the log-rank test, respectively). Thus, transcriptional 
activity of HPV E6 and E7 oncogenes was a prognostic 
marker associated with favorable outcome for cervical 
cancer.
miR-9 was upregulated in HPV-positive cervical 
tumors
The HPV status of the 101 cervical tumors was 
correlated to the corresponding miRNA expression 
profiles, which have been determined in our previous 
study [16]. In this way, four HPV-related miRNAs were 
identified, including upregulated miR-9, miR-205 and 
miR-224, as well as downregulated miR-29b (Table 2). 
Table 1: Patient characteristics.*
Age at diagnosis (mean ± s.d.) 51.4 ± 12.7
Tumor histology
   Squamous 89
   Adenocarcinoma 10
   Clear cell 2
   Undifferentiated 1
FIGO stage*
   I 28
   II 36
   III 32
   IV 5
Histological grade
   Well 4
   Moderate 48
   Poorly 31
   Undetermined 18
*FIGO represents International Federation of Gynecology 
and Obstetrics.
Figure 2: miR-9 expression was significantly correlated 
with HPV expression status. (A) miR-9 expression profiles 
in four selected groups: HPV-negative tumors (n=14), all HPV-
positive tumors (n=87), HPV16-positive tumors (n=57, with 
two double HPV infection cases excluded) and HPV18-positive 
tumors (n=15), respectively. (B) The impact of HPV E6 and 
E7 oncogenes on miRNA expression. HPV16 E6 or E7 genes 
were stably expressed in NIKS keratinocytes, and the impact 
on miRNA expression was determined by profiling analysis 
and comparison with negative control cells expressing vehicle 
vector. Among all miRNAs included in the analysis, four most 
upregulated ones are presented here. (C) Activation of miR-9 
by HPV oncogenes in other cell types. HPV16 E6 or E7 were 
stably expressed in primary HFK keratinocytes and epithelium 
RPE cells, respectively, and the impact on miRNA expression 
was determined. miR-9 was the most activated miRNA in both 
HFK and RPE cells.
Table 2: HPV-associated miRNAs in cervical cancer.





The fold change values were Log2 transformed. Statistical 
significance was calculated with Student’s t-test and the 
resulting p-values were further adjusted for multiple 
testing with the false discovery rate approach.
Oncotarget4www.impactjournals.com/oncotarget
Among all miRNAs included in the analysis, miR-9 was 
most significantly associated with tumor HPV status 
(upregulated by 2.2-fold in HPV-positive tumors, false 
discovery rate = 0.002). miR-9 expression was further 
correlated to individual HPV types. As shown in Figure 
2A, miR-9 was significantly upregulated in HPV-positive 
tumors compared with HPV-negative tumors (P = 2.7E-05 
with Student’s t-test). When correlated to specific HPV 
strains, miR-9 overexpression in HPV18-positive tumors 
was relatively modest and not statistically significant (P = 
0.11 with Student’s t-test). In contrast, miR-9 was strongly 
upregulated in HPV16-positive tumors compared with 
both HPV18-positive and HPV-negative tumors, with P 
= 0.007 and P = 2.2E-06 by Student’s t-test, respectively.
Interestingly, miR-9 has been identified as a 
biomarker for favorable prognosis in cervical cancer in our 
previous study [16]. Consistently, in this expanded analysis 
of 101 cervical cancer cases, miR-9 was also shown to be 
a significant prognostic marker, with P = 0.008 and 0.009 
for five-year overall survival and recurrence-free survival, 
respectively by the log-rank test. To evaluate potential 
dependency of miR-9 expression on HPV transcriptional 
activity, the 101 patients were stratified into either HPV-
positive group or HPV-negative group, and the prognostic 
significance of miR-9 was evaluated for each patient 
cohort separately. Cox regression analysis showed that 
miR-9 was no longer a significant marker, with P = 0.06 
and 0.11 for five-year overall survival and recurrence-free 
survival, respectively for the HPV-positive cohort, and P = 
0.54 and 0.24 for five-year overall survival and recurrence-
free survival, respectively for the HPV-negative cohort. 
Thus, this outcome analysis indicated that the prognostic 
significance of miR-9 was mainly a result of its association 
with tumor HPV status.
miR-9 was activated by HPV E6 oncogene
To determine HPV genes responsible for miR-
9 activation, E6 and E7 genes from HPV16 were 
individually expressed in immortalized human foreskin 
keratinocytes (NIKS), which are considered as a natural 
host for HPV [18]. The impact of viral gene expression 
was determined by miRNA expression profiling and 
comparison with negative control cells expressing 
empty vehicle vector. Strikingly, miR-9 was the most 
activated miRNA, upregulated by 45-fold as a result 
of E6 expression (Figure 2B). E7 expression also led 
to five-fold upregulation of miR-9. In comparison, the 
expression changes for all other miRNAs were much 
smaller (< 3-fold). Thus, the in vitro cell profiling data 
were consistent with the result from cervical tumor tissue 
profiling, indicating that upregulation of miR-9 expression 
in cervical cancer was a result of HPV oncogene activity.
In addition to NIKS cell analysis, the causative 
role of HPV activity on miR-9 activation was also 
evaluated in other cell types, including primary foreskin 
keratinocyte HFK and retinal pigment epithelium (RPE) 
cells. In both cellular systems, E6 and E7 genes from 
HPV16 were individually expressed and the impact on 
miRNA expression was evaluated by profiling analysis. 
Interestingly, in both HFK and RPE cells, miR-9 was the 
most upregulated miRNA by HPV E6 oncogene (Figure 
2C). Thus, miR-9 activation by HPV E6 was a general 
mechanism observed in multiple cell types.
HPV-induced miR-9 activation was independent 
of p53 activity
Deactivation of tumor suppressor p53 is a major 
function of HPV E6 oncogene in cervical cancer. 
Thus, we determined whether HPV-induced miR-9 
activation is a result of p53 deactivation by E6. To this 
end, an E6 mutant F2V (Phe-2 to Val mutation) was 
studied. Our previous work indicated that F2V mutant 
was defective for p53 degradation but competent for 
Figure 3: miR-9 activation by HPV E6 was independent 
of p53 activity. (A) p53 protein expression in NIKS cells 
expressing HPV E6 or E6 mutant F2V by Western blot. As a 
positive control, nocodazole (50ng/ml) was added to the medium 
to upregulate p53 expression in NIKS vector control cells. p53 
protein was detected in F2V-expressing cells and vector control 
cells, but not in E6-expressing cells. The p53 and β-actin blots 
were exposed for 50 and 4 seconds, respectively. (B) miR-9 was 
the most upregulated miRNA in F2V-expressing NIKS cells. 
Three most upregulated miRNAs among all miRNAs included in 
the analysis, as identified by expression profiling, are presented 
in the graph.
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immortalization of mammary epithelial cells and 
abrogation of cell cycle checkpoint [19, 20]. In this study, 
F2V mutant was expressed in NIKS keratinocytes, and 
the impact on miRNA expression was determined by 
profiling analysis. As shown in Figure 3A, p53 protein 
expression was suppressed by E6, but not by F2V mutant, 
a result consistent with our previous observations [20]. 
miRNA expression profile of F2V-expressing cells was 
determined and compared with that of E6-expressing cells. 
Interestingly, miR-9 was the most significantly activated 
miRNA by F2V, upregulated by over 60-fold as compared 
with the negative control vector cells (Figure 3B). Thus, 
miR-9 was significantly upregulated by both E6 and F2V, 
indicating that its activation by HPV E6 was independent 
of the p53 pathway.
Identification of miR-9 targets
miR-9 can target a wide array of genes in a manner 
dependent on the cellular context [21]. To determine 
potential functional relevance of miR-9 activation in 
cervical cancer, genes targeted by miR-9 were determined 
Figure 4: Identification and validation of miR-9 targets. (A) Systematic identification of miR-9 targets by combining 
computational target prediction with RNA-seq expression profiling. Transcriptome-wide miRNA target prediction was performed with 
miRDB. In parallel, RNA-seq experiment was performed to globally identify genes downregulated by miR-9 overexpression. Among all 
genes expressed in HeLa cells, 38 were both predicted miR-9 targets and downregulated by miR-9 as revealed by RNA-seq. (B) Real-time 
RT-PCR to validate miR-9 targets. Among 23 selected target candidates, 18 were downregulated by over 40% (<60% remaining expression 
level). (C) Luciferase reporter assays to validate miR-9 target sites in the 3’-UTR of FSTL1 or ALCAM mRNA. The 3’-UTR sequences of 
FSTL1 and ALCAM were individually cloned into pmirGLO, and luciferase activities were measured after co-transfection of individual 
3’-UTR constructs with miR-9 and negative control RNA, respectively. The impact of FSTL1 or ALCAM 3’-UTR on firefly luciferase 
activity was evaluated by comparing with the negative control and normalized by Renilla luciferase signals. (D) Downregulation of FSTL1 
and ALCAM in E6-expressing NIKS cells as compared with vector control cells.
Oncotarget6www.impactjournals.com/oncotarget
by combined computational and experimental analyses. 
First, putative gene targets of miR-9 were computationally 
predicted using our previously developed algorithm, 
with prediction data retrieved from miRDB [22, 
23]. The superior performance of miRDB over other 
common algorithms has recently been demonstrated in 
an independent comparative analysis [24]. Among all 
6,487 genes expressed in cervical cancer HeLa cells, 186 
were predicted to be miR-9 targets by miRDB (Figure 
4A). Then, high-throughput RNA sequencing (RNA-
seq) analysis was performed to globally validate these 
predicted gene targets in HeLa cells. Overexpression of 
miR-9 had a significant impact on the transcriptome of 
HeLa cells. Altogether, 185 genes were downregulated by 
at least 50%, including 38 genes that were predicted to 
be miR-9 targets by miRDB (Figure 4A, complete gene 
list presented in Supplementary Table 1). The enrichment 
of computationally predicted miR-9 targets among all 
downregulated genes (20.5%) was much higher than 
the transcriptome background (2.9%, P < 10-22 with the 
hypergeometric test). Thus, these 38 genes were likely to 
be directly targeted by miR-9.
Real-time RT-PCR experiments were performed 
to validate the RNA-seq results. Twenty-three potential 
cancer-related miR-9 targets, as identified by both RNA-
seq and computational target prediction, were selected for 
further validation. Among them, 18 were downregulated 
by over 40% as validated by real-time RT-PCR (Figure 
4B). Two qPCR-validated miR-9 targets, FSTL1 and 
ALCAM were particularly interesting, as both genes 
were among the most suppressed targets and have 
been reported to regulate cell mobility [25, 26]. Thus, 
FSTL1 and ALCAM were selected for further functional 
characterization.
Luciferase reporter assays were performed to 
confirm direct targeting of FSTL1 and ALCAM by miR-
9. To this end, the 3’-UTR sequences of FSTL1 and 
ALCAM were individually cloned into pmirGLO, which 
is a dual-luciferase miRNA target expression vector. The 
luciferase activity was measured after co-transfection 
of the constructed expression vectors with miR-9 or 
negative control RNA in 293T cells. For both FSTL1 and 
ALCAM constructs, overexpression of miR-9 significantly 
suppressed the luciferase activity as compared with the 
negative control RNA (Figure 4C). Thus, miR-9 was able 
to regulate the 3′-UTR of FSTL1 or ALCAM mRNA, 
leading to suppression of target protein expression. Given 
that miR-9 was activated by HPV E6, we hypothesized that 
FSTL1 and ALCAM expression should be downregulated 
in the presence of HPV E6. To this end, the expression 
levels of FSTL1 and ALCAM were determined by real-
time RT-PCR in HPV16 E6-expressing NIKS cells. As 
shown in Figure 4D, both FSTL1 and ALCAM mRNA 
expression levels were significantly decreased in HPV16 
E6-expressing NIKS cells as compared with vector control 
cells. Combined together, these results indicated that 
FSTL1 and ALCAM were direct targets of miR-9.
miR-9 and HPV E6 were positive regulators of 
NIKS cell migration
miR-9 has been implicated in regulation of cancer 
metastasis; however, it could exert opposing roles (either 
promoting or suppressing metastasis) depending on cancer 
type or cellular context [21]. To characterize the functional 
relevance of miR-9 activation by HPV, we evaluated the 
impacts of miR-9 and HPV E6 on regulating the motility 
of NIKS cells with transwell migration assays. To this 
end, expression of E6 resulted in significantly increased 
motility of NIKS cells by 2.5-fold as compared with 
control cells expressing the vehicle vector (Figure 5A). 
Figure 5: HPV E6 and miR-9 were both positive regulators of NIKS cell motility. (A) HPV16 E6 expression led to increased 
mobility of NIKS cells as compared with control cells expressing vehicle vector. (B) Transient overexpression of miR-9 or knockdown 
of miR-9 targets (FSTL1 or ALCAM) by siRNA led to increased mobility of NIKS cells as compared with the negative control RNA 
transfection.
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We hypothesized that the effect on cell migration by 
E6 was likely through activation of miR-9, as miR-9 
expression was significantly upregulated in E6-expressing 
cells (Figure 2). To test potential direct impact of miR-
9 on cell motility, miR-9 was overexpressed by transient 
transfection in NIKS cells that had no E6 expression. 
As a result, the mobility of miR-9 expressing cells was 
significantly increased by 4.9-fold compared with that 
of negative control cells (Figure 5B). Furthermore, we 
also determined the roles of two validated miR-9 targets, 
FSTL1 and ALCAM in regulating cell migration. RNAi 
knockdown experiment was performed to suppress 
the expression of FSTL1 and ALCAM in NIKS cells, 
respectively. The remaining mRNA levels of FSTL1 and 
ALCAM were 8% and 15% after siRNA knockdown, 
respectively as determined by real-time RT-PCR. As 
shown in Figure 5B, knockdown of ALCAM or FSTL1 led 
to increased mobility of NIKS cells (3.2-fold and 3.0-fold, 
respectively), which mimicked the functions of miR-9 and 
HPV E6 for promoting NIKS cell migration.
DISCUSSION
HPV transcriptional activity in cervical cancer
Although HPV genomic DNA is detected in 
almost all cervical cancer cases [3, 4], persistent 
transcriptional activity of HPV oncogenes has not been 
well characterized. Specifically, the presence of E6 and 
E7 transcripts indicates active functional roles of HPV 
in cervical cancer maintenance and progression. To this 
end, we have recently developed real-time RT-PCR assays 
to profile E6 and E7 from thirteen high-risk HPV types, 
which represents one of the most comprehensive methods 
to date for transcriptional profiling of HPV oncogenes 
[17]. With these assays, we have detected transcriptional 
activities of ten HPV strains from 86% of all cervical 
tumors included in our analysis. Interestingly, these 
HPV-positive patients had significantly better survival 
outcome compared with HPV-negative patients. Thus, 
HPV transcriptional activity was a favorable prognostic 
marker for cervical cancer. We have previously shown 
that HPV transcriptional activity was detected in 81% of 
oropharyngeal cancers and was predictive of favorable 
survival outcome [17]. Thus, for both types of cancer, 
HPV activity serves as a biomarker for favorable 
prognosis. This is consistent with recent observations 
that HPV-positive oropharyngeal tumors harbor less gene 
mutations and are more responsive to chemoradiation 
therapy compared with HPV-negative oropharyngeal 
tumors [27, 28]. Currently, there are multiple ongoing 
clinical trials to evaluate modified treatment plans for 
oropharyngeal cancer patients based on tumor HPV status, 
with the goal of improving therapeutic effectiveness. In 
comparison, the HPV status of cervical cancer has not 
been well utilized for guiding treatment decisions. In this 
study, we showed that a small, but significant fraction 
(14%) of cervical cancers were HPV negative and with 
poor survival outcome. These patients could potentially 
benefit from modified therapies as they responded poorly 
to standard chemoradiation treatment. 
miR-9 activation by HPV in cervical cancer
miR-9 exerts diverse roles in many types of tissue. 
In particular, miR-9 plays a prominent role in neurogenesis 
by regulating targets involved in proliferation, migration 
and differentiation of neural progenitor cells [21]. 
Relevant to this work, recent studies show that miR-9 
is functionally involved in regulating cancer metastasis, 
either promoting or suppressing metastasis depending 
on the tissue context [29-32]. As to cervical cancer, 
inconsistent results have been reported regarding potential 
change of miR-9 expression compared with normal 
cervix tissues. One study [14] showed increased miR-9 
expression in tumors while a few other studies reported 
no significant change (reviewed in [33]). The discrepancy 
is likely a result of varying proportions of HPV-infected 
tumor or normal control tissues included in those studies, 
as the HPV status of the tissues had not been determined. 
By age 50, at least 80% women in the US will have been 
infected with HPV (http://www.cdc.gov). Thus, a large 
proportion of tumor as well as normal cervix tissues are 
infected by HPV. Our work indicated that miR-9 was 
upregulated by HPV in both cancer tissues and non-cancer 
normal cells. Thus, activation of miR-9 is a result of HPV 
infection preceding the development of cancer. In this 
case, no miR-9 expression change would be observed if 
both tumor and normal tissues were HPV positive.
Our study showed that miR-9 was specifically 
activated by HPV in a p53-independent manner. However, 
the mechanisms of miR-9 activation by HPV are yet to 
be discovered. Interestingly, Wilting et al. showed that 
the miR-9 locus is associated with a frequent abnormal 
chromosomal gain in cervical cancer [14]. Thus, miR-9 
activation in cervical cancer could be a result of elevated 
chromosomal instability induced by HPV infection. This 
hypothesis is consistent with the extensive roles of HPV 
played in inducing genomic instability in carcinogenesis 
(reviewed in [34]). However, extensive mechanistic 
studies would be needed to elucidate how miR-9 is 
activated by HPV, which is beyond the scope of the 
current study.
Similar to cervical cancer, we have recently reported 
upregulated miR-9 expression associated with HPV 
activity in oropharyngeal cancer [35], an observation 
confirmed by an independent study [36]. Thus, activation 
of miR-9 by HPV is a general phenomenon that is not 
only confined to cervical cancer. Our current work 
identified multiple genes that were targeted by miR-9. 
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Both activation of miR-9 and suppression of its targets 
resulted in increased mobility of HPV hosting cells, which 
could eventually lead to metastatic cancer. Thus, our work 
helps to understand the molecular mechanisms as well 
as identify novel therapeutic targets for HPV-induced 
cancers including cervical cancer, oropharyngeal cancer, 
and potentially other types of cancer as well.
MATERIALS AND METHODS
Patient tumor samples
All 101 cervical cancer patients included in this 
study were treated at the Washington University School 
of Medicine in St. Louis, with patient characteristics 
summarized in Table 1. This study was approved by the 
Human Research Protection Office at the Washington 
University. All these archived tumor tissues have been 
described in detail and analyzed previously for miRNA 
expression studies [16]. In brief, tumor tissues were 
collected prior to radiotherapy and processed by the Tissue 
Procurement Core Facility at Washington University. 
Then, total RNA was isolated from the archived tumors as 
described in detail previously [16].
Expression profiling of HPV and miRNAs
HPV expression profiling of the tumor samples was 
performed using PCR-based assays as described in our 
recent study [17]. In brief, these assays were designed to 
detect and quantify E6 and E7 transcripts from thirteen 
high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 
59, 66, and 68). All oligonucleotide primers in the assays 
were purchased from Sigma-Aldrich. Reverse transcription 
(RT) reaction was performed with High Capacity cDNA 
Reverse Transcription Kit (Life Technologies). Real-time 
PCR was performed to quantitate the cDNA with Power 
SYBR Green PCR Master Mix (Life Technologies) and 
HPV type-specific primers. Each E6 and E7 assay from 
all 13 HPV types was performed separately in a 384-
well PCR plate, with PCR running protocol described 
previously [17]. In addition, both GAPDH and β-actin 
expression levels were used as the internal reference 
control for real-time PCR data normalization.
miRNA expression profiling was performed 
using a PCR-based method, with detailed experimental 
protocol described in our previous study [37]. In brief, 
the RT reactions were done with the High Capacity cDNA 
Reverse Transcription Kit (Life Technologies). Each RT 
reaction included total RNA as the template and a pool 
of miRNA-specific RT primers. Real-time PCR was 
performed individually for each of 96 cancer-related 
miRNAs with Power SYBR Green PCR Master Mix 
(Life Technologies). These cancer-related miRNAs were 
selected based on mining of public literature [37]. Raw 
PCR data were normalized using a quantile-based scaling 
method as described previously [37]. 
Survival analysis
Statistical analysis was performed with the R 
package (http://www.r-project.org/). Univariate Cox 
proportional hazards regression analysis was done to 
evaluate the prognostic significance of HPV or miR-
9 expression in cervical tumors, and the p-values were 
calculated with the log-rank test. Five-year overall survival 
and recurrence-free survival were used as the end points 
to represent disease outcome. Overall survival was defined 
as the time interval between treatment start date and the 
date of death from any cause; recurrence-free survival was 
defined as the time interval between treatment start date 
and the date of death or first failure.
Cell culture and transfection
HeLa cells were purchased from American Type 
Culture Collection (ATCC). Primary human foreskin 
keratinocytes (PHK) were prepared from neonatal 
foreskins obtained from the University of Massachusetts 
Memorial Hospital as described [38]. Immortalized 
human foreskin keratinocyte cells (NIKS) with stable 
expression of HPV E6, E6 mutant F2V or E7 were 
established using the pBabe retroviral system as described 
in our previous study [39]. Both PHK and NIKS cells 
were maintained on mitomycin C–treated J23T3 feeder 
cells in F-medium as described [39]. RPE1 is a human 
telomerase reverse transcriptase–expressing human retinal 
pigment epithelium cell line obtained from Clonetech 
Laboratories. RPE1 cells were cultured in 1:1 DME and 
Ham’s F12 media (Sigma-Aldrich) as described [19]. 
miRNA mimics, siRNAs and negative control RNA (a 
random sequence) were purchased from Sigma-Aldrich. 
Cells were transfected with 60 nM of either miRNA or 
siRNA using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s recommended protocol.
Western blot
Cells were lysed with RIPA buffer (Thermo 
Scientific). Then, the lysate was centrifuged and protein 
supernatant was loaded to SDS–PAGE. Protein bands on 
the gel were transferred to Immun-Blot PVDF membrane 
(Bio-Rad). The membrane was first blocked with 5% milk 
in TBS buffer and then incubated with primary anti-p53 
mAb (BD Biosciences) or anti-β-Actin mAb (Sigma-
Aldrich). After washing with TBS buffer, the blot was 
incubated with secondary anti-mouse IgG mAb conjugated 
with horseradish peroxidase (Thermo Scientific), and 
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bound antibodies were visualized by HRP substrate 
(Millipore) and detected on X-ray films.
RNA-seq
High-throughput RNA sequencing (RNA-seq) 
was performed as described in our previous study [40]. 
In brief, total RNA was extracted from the cells with the 
mirVana kit (Life Technologies). Ribosomal RNA (rRNA) 
was removed from total RNA with the RiboMinus kit (Life 
Technologies) and custom rRNA oligonucleotide probes. 
Then, the rRNA-depleted RNA samples were used to 
construct sequencing libraries with the NEBNext mRNA 
Library Prep kit (New England BioLabs). Amplified 
cDNA libraries were loaded into HiSeq 2000 (Illumina) 
for sequencing at the Genome Technology Access Center 
at the Washington University. Raw sequence reads were 
preprocessed with a custom bioinformatics pipeline 
for clustering before mapping to the RefSeq human 
transcriptome with Bowtie [41]. Mapped sequence reads 
were then normalized using the RPKM method (reads per 
kb per million), and compared across samples to evaluate 
changes in transcript abundance.
Real-time RT-PCR for target validation
Reverse transcription was performed with the High 
Capacity RT kit (Life Technologies). All PCR primer 
sequences were retrieved from PrimerBank [42]. Real-
time PCR was performed to validate the downregulation of 
candidate miRNA targets as identified by RNA-seq, using 
the standard PrimerBank PCR protocol as described [43]. 
GAPDH and β-actin were included as internal controls for 
expression data normalization. Potential target expression 
changes were determined with the 2ΔΔCt method by 
comparison with the negative control PCR.
Luciferase reporter assay
The 3′-UTRs of human FSTL1 and ALCAM were 
amplified by PCR and cloned into pmirGLO vector 
(Promega). For luciferase reporter assays, each construct 
was co-transfected with miRNA mimics or negative 
control RNA (60 nM) into 293T cells in a 96-well plate 
with Lipofectamine 2000 (Life Technologies). Twenty-
four hours post transfection, luminescent signals from 
firefly luciferase were determined with a Luminoskan 
Ascent luminometer (Thermo Fisher Scientific) and 
normalized by luminescent signals from Renilla luciferase.
Transwell migration assay
Migration assays were performed using 8.0 μM 
polycarbonate transwell inserts (Corning) according to 
manufacturer’s instructions. Briefly, the bottom wells 
were filled with 600 μL medium containing 10% bovine 
serum. A total of 1x105 cells in 100 µl serum-free medium 
were plated in the upper inserts and allowed to migrate for 
24 hrs. Non-migrated cells were removed with a cotton 
swab, while cells that had migrated were fixed and stained 
with Hema-3 (Fisher Scientific) for counting. The fold 
change of cell migration was calculated by comparing 
the cells expressing miR-9 and HPV E6 with the cells 
expressing negative control RNA and empty vehicle 
vector, respectively.
SUPPLEMENTARY DATA
Supplementary data are available at the journal’s 
website.
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